The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
The product is expected to be available in a week’s time
It plans to deliver over 300 million doses to the Indian government
DCGI approved the drug based on the review of clinical data
The drug will be marketed under the brand name Molnaflu
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
The hospital has recently launched Radionuclide therapy
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1
Prucalopride medicine in the form of Orally Disintegrating Strips are most convenient dosage form for geriatric patients
Subscribe To Our Newsletter & Stay Updated
